Patent Application
20220218571
The present invention relates to the field of drug delivery systems, specifically to a hydrogel drug delivery composition.
Oral disease is a very common disease in human. In most cases, the treatment of oral diseases only requires local medication, not systemic medication. For some patients, systemic medication may cause serious side effects. Moreover, systemic medication can easily lead to drug resistance in the body, reducing the efficacy of drugs. In addition, the oral environment is complex, and many factors affect the health of the oral cavity. For example, long-term use of antibiotics will destroy the normal flora of the oral cavity. Researchers have been looking for a delivery system that can effectively release drugs in the oral cavity in a targeted manner.
Periodontal disease is a prevalent and chronic inflammatory condition that affects the surrounding tissues of the teeth including gingiva, periodontal ligament, and alveolar bone resulting in pocket formation, mobility, bone loss, and eventually lead to the loss of tooth. In addition to the pathogenic bacterial population, the host immune response, which aims at protecting host tissues from bacterial aggression, also acts as a mediator of the periodontal damage[1]. Current treatment strategies aim at reducing bacterial load by mechanical therapy and administration of antimicrobial agents[2, 3]. Additionally, host modulation agents have been utilized to ameliorate inflammation and prevent disease progression[4, 5]. Their efficacy on halting the alveolar bone loss, which is the major destructive and non-reversible hallmark of periodontal disease, is limited. Therefore, there is an unmet clinical need to develop novel therapies that would prevent bone erosion and regenerate the lost alveolar bone.
Glycogen synthase kinase 3 beta (GSK3β) is a multi-tasking serine/threonine kinase with crucial roles in several physiological processes including inflammation and bone homeostasis. It has been shown to play a critical role in the host inflammatory response[6-8] and bone homeostasis[9] as a negative regulator, suggesting that inhibitors of GSK3β may provide therapeutic effects for inflammatory and bone metabolic diseases[10]. Particularly, a GSK3β inhibitor (SB216763) has been studied in periodontal disease and data confirmed its therapeutic benefits in preventing alveolar bone loss associated with periodontal disease[11] During the last decade, several selective GSK-3β inhibitors have been synthesized and tested in clinical trials at various phases[12, 13]. In particular, 6-bromoindirubin-3′-oxime (BIO), a potent GSK3β inhibitor with an enzymatic IC50 of 5 nM, has exhibited anti-inflammatory[7, 8] and strong bone and teeth anabolic effects[14-20]. Due to the involvement of GSK3 in multiple physiological processes, however, systemic administration may cause serious adverse side effects (e.g., diarrhea, hypoglycemia, tumorigenesis)[21-23]. Hence, it is necessary to limit and restrict its biological action primarily at the intended site of action. Local delivery of BIO into the periodontal pocket will permit direct targeting of periodontal tissue, achieving high local concentrations along with minimizing systemic toxicities. However, the poor aqueous solubility and rapid clearance of BIO from the periodontal pockets post major challenges to its effective local delivery.
Statins, which were developed as 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors, have been widely used to treat cardiovascular diseases for decades. Mundy et al. reported that two statins, simvastatin (SIM) and lovastatin, have strong bone anabolic effects that were attributed to induction of the bone inducing factor bone morphogenic protein-2 (BMP-2). Later, statins are also noted for their anti-inflammatory effects[56]. Major efforts have been invested since then, attempting to validate this finding. The results remain controversial, however, in part due to the first-pass metabolism in the liver, which limits the amounts that reach bone when given orally and have prevented their clinical application to strengthen skeletal bones or treat periodontitis. Local applications of simvastatin are hindered by its poor water solubility (https://www.drugbank.ca/drugs/DB00641).
Thermoresponsive hydrogel formulations injected into the periodontal pocket would be a promising option for the local delivery of BIO or SIM to prevent the bony defects associated with periodontitis. Poloxamer 407 (Pluronic F127), a frequently used formulation excipient that has been approved by U.S. FDA for pharmaceutical applications, is a triblock amphiphilic copolymer consisting of a center block of polypropylene oxide flanked by two polyethylene oxide blocks (PEO101 PPO56 PEO101)[24-27]. It has been used extensively in controlled drug and cell delivery[28]. Its unique thermoresponsive gelation property in aqueous solutions (20-35% w/v) makes it an appealing carrier material for periodontal drug delivery and other similar applications[29, 30] The amphiphilic F127 polymer enhances the solubility of hydrophobic drugs at room temperature by forming micelles. When exposed to physiological temperature, the polymer solution forms a hydrogel, holding encapsulated drugs in its collapsed micellar structure to provide sustained release kinetics. F127 is also known to be non-toxic and biocompatible[30]. The constant flow of crevicular fluid, the poor bone-adhesion and mechanical properties of F127 hydrogel, however, would significantly limit the bioavailability of the payload drug in the periodontal pocket.
Therefore, there is a need to improve binding of hydrogel to the hard tissues and develop a novel hydrogel drug delivery system for effective drug release in topical site.
In one aspect, the present disclosure provides a drug delivery composition comprising a therapeutic agent and a poloxamer, wherein the poloxamer is modified to be capable of adhering to a surface of bones or teeth.
Poloxamers are nonionic triblock copolymers composed of a central hydrophobic chain of polyoxypropylene (poly(propylene oxide)) flanked by two hydrophilic chains of polyoxyethylene (poly(ethylene oxide)). Preferably, the poloxamer is modified by pyrophosphate, bisphosphonate, dopamine, acidic peptide, or tetracycline and a derivative thereof.
More preferably, the poloxamer is a pyrophosphorylated poloxamer or a mixture of poloxamer and pyrophosphorylated poloxamer.
In the embodiments of the present disclosure, wherein
the poloxamer is selected from the group consisting of Pluronic L31, L35, F38, L42, L43, L44, L61, L62, L63, L64, P65, F68, L72, P75, F77, L81, P84, P85, F87, F88, L92, F98, L101, P103, P104, P105. F108, L121, L122, L123, F127, 10R5, 10R8, 12R3, 17R1, 17R2, 17R4, 17R8, 22R4, 25R1, 25R2, 25R4, 25R5, 25R8, 31R1, 31R2, 31R, and a mixture thereof; preferably, the poloxamer is poloxamer 407 (Pluronic F127);
the therapeutic agent includes anti-inflammatory compounds, bone anabolic compounds, bone antiresorptive compounds, anti-cancer compounds, statins, and antimicrobial compounds; preferably, the therapeutic agent is a GSK3-beta inhibitor or a statin.
The GSK3-beta inhibitors may be used in this invention are listed in Table 1.
In one embodiment of the present disclosure, wherein the GSK3-beta inhibitor is selected from the compounds listed in Table 1, such as indirubin and its derivatives, lithium, beryllium, zinc, and a mixture thereof; preferably, the GSK3-beta inhibitor is 6-bromoindirubin-3′-oxime, lithium, or zinc.
The statins may be used in this invention include atorvastatin (Lipitor), fluvastatin (Lescol, Lescol XL), lovastatin (Mevacor, Altoprev), pravastatin (Pravachol), rosuvastatin (Crestor), simvastatin (Zocor), and pitavastatin (Livalo).
Preferably, the composition is in a form of hydrogel and the hydrogel is thermosensitive.
In another aspect, the present disclosure provides a method of manufacturing the drug delivery composition comprising,
In another aspect, the present disclosure provides a method of treating an oral disease comprising administering the drug delivery composition in situ at a topical site to a subject in need thereof.
Preferably, the topical site is a tooth and the oral disease is a dental disease, more preferably periodontitis. The composition is capable of releasing the therapeutic agent to treat the oral disease over a period of at least 2 days, and the composition is adherent only to the topical site.
The embodiments of the present disclosure will be described in detail below with reference to the embodiments. However, a person having ordinary skill in the art will understand that the following embodiments are merely to illustrate present disclosure and are not intended to limit the scope of the disclosure. For those embodiments in which specific conditions are not specified, they were carried out according to the conventional conditions or the conditions recommended by the manufacturer. For those used reagents or instruments of which the manufacturers are not indicated, they were all commercially available conventional products.
Pluronic F127 and pyrophosphate were purchased from Sigma-Aldrich (Saint Louis in Mo., USA). BIO was synthesized according to literature[31]. Dense Ceramic Hydroxyapatite discs (0.5″ diameter and 0.08″ Thick) were obtained from Clarkson Chromatography Products, Inc. (South Williamsport, Pa. USA). Mouse osteoblast MC3T3-L1 cells were acquired from ATCC (Manassas, Va., USA). Fetal bovine serum (FBS, BenchMark™) was acquired from Gemini BenchMark (West Sacramento, Calif.). Minimum Essential Media (alpha-MEM), and trypsin-EDTA were purchased from GIBCO (Grand Island, N.Y., USA). Cell Counting Kit-8 (CCK-8) was bought from Dojindo Molecular Technologies, Inc. (Rockville, Md. USA). All other solvents and reagents, if not specified, were acquired from either Acros Organics (Morris Plains, N.J., USA) or Fisher Scientific (Pittsburgh, Pa., USA).
Pluronic F127 (1.0 g, 0.079 mmol) and 4-toluenesulfonyl chloride (151 mg, 0.79 mmol) were dissolved in dry dichloromethane. Pyridine (62 μL, 0.79 mmol) was then added and the resulting solution was stirred for 24 hr at 21° C. After adding dichloromethane (80 mL), the resulting solution was washed with HCl (1 M, 20 mL) and brine (80 mL×2). After washing, the organic phase was separated and dried over MgSO4. The solution was filtered, concentrated and the residue was purified on a LH-20 column to produce 922 mg of the final product, yield: 90%. 1H NMR (CDCl3, 500 MHz) δ ppm 7.78 (d, J=3.0 Hz, 4H), 7.33 (d, J=3.0 Hz 4H), 4.14 (t, J=5.0 Hz, 4H), 3.77 (t, J=4.5 Hz, 8H), 3.59-3.55 (m, 872H), 3.50-3.44 (m, 142H), 3.38 (m, 65H), 2.44 (s, 6H), 1.12 (t, J=5.0 Hz, 195H); 13C NMR (CDCl3, 125 MHz) δ ppm 144.7, 133.0, 129.8, 127.9, 75.5, 75.4, 75.1, 73.4, 73.0, 72.9, 72.7, 69.2, 68.7, 21.6, 17.5, 17.3.
The tosylated Pluronic F127 (1.0 g, 0.077 mmol) and tris(tetra-n-butylammonium) hydrogen diphosphate [(n-Bu4N)3(HO)P2O6] (0.31 mmol, 280 mg) were dissolved in dry acetonitrile. The solution was stirred at 21° C. until the starting materials completely disappeared (˜3 hr, monitored by TLC). After removal of the solvents, the residue was dissolved in water (20 mL) and dialyzed (MWCO=12-14 kDa) against NaCl solution (0.1 mol/L) overnight to exchange tetrabutyl ammonium to sodium. The resulting solution was then dialyzed against distilled water to remove the excessive NaCl. The resulting solution was then lyophilized to obtain 859 mg of the final pyrophosphorylated Pluronic F127 (F127-PPi) product, yield: 85%. The synthesis path is shown in
1H NMR (CDCl3, 500 MHz) δ ppm 4.16 (t, J=5.0 Hz, 4H), 3.78 (t, J=4.5 Hz, 8H), 3.59-3.54 (m, 872H), 3.50-3.44 (m, 142H), 3.39-3.36 (m, 65H), 1.13 (t, J=5.0 Hz, 195H); 13C NMR (CDCl3, 125 MHz) δ ppm 75.5, 75.4, 75.1, 73.4, 73.0, 72.9, 72.8, 72.7, 70.6, 17.5, 17.3; 31P NMR (202.5 MHz, CDCl3): δ (ppm)=−7.70 (d, J=20.2 Hz), −7.91 (d, J=20.2 Hz).
To determine the PPi content, F127-PPi was hydrolyzed in 1 M HCl for 2 hr at 100° C. to release the phosphate. After removal of F127 with chloroform extraction, an equal volume of 1 M HCl solution containing 0.5% (w/v) ammonium molybdate and 2% (w/v) ascorbic acid was added. The samples were incubated at 37° C. for 2 hr then their absorbance at 820 nm was measured using a UV spectrometer[49]. Eighty percent terminal hydroxyl groups of F127 was found to has been pyrophosphorylated.
PF127 hydrogel formulations with predetermined polymer concentrations (20, 25 and 30% w/v) were prepared by mixing F127-PPi and F127 at different ratio (0:100, 25:75, 50:50, 75:25, 100:0% w/w). Briefly, the desired amount of F127-PPi and F127 was dissolved in PBS (pH 7.4) with stiffing in an ice-water bath (˜4° C., to prevent gelation) until a clear solution (PF127) was obtained and then stored at 4° C. overnight. BIO was then dissolved in the polymer solutions by continuous stirring at 4° C., the obtained solutions were filtered through 0.8 μm filter syringes.
To assess the binding potential of the formulated hydrogels to hydroxyapatite or HA, which constitute the main inorganic component of bone and teeth, an in vitro binding study was done using HA discs. Briefly, polymer solutions (25% w/v) were prepared, containing 100 μM of BIO, with different ratios of F127-PPi and F127 (0:100, 25:75, 50:50, 75:25, and 100:0% w/w) to optimize binding affinity. Hydrogels (1 mL) were formed on HA disc placed in plastic wells at 37° C., and the hydrogels were allowed to stabilize for 15 min. After that, HA discs, on which hydrogels are formed, were inverted with temperature maintained at 37° C. by keeping the inverted hydrogels inside the water bath (37° C.). The binding time of hydrogel to HA disc was measured. The binding experiment was performed in triplicate. Based on this study, one formulation was selected for all subsequent experiments.
The aqueous solubility of BIO in PF127 and F127 solutions was assessed in this experiment. The solubility values of BIO were measured at dissolution equilibrium after adding the BIO to the PF127 and F127-containing media for a predetermined period of time, as reported previously[32]. Specifically, an excessive amount of BIO was added to different concentrations of PF127 or F127 solutions in microcentrifuge tubes. The suspensions were mixed on a rotor at 4° C. for 48 hr to achieve dissolution equilibrium. At 4° C., the suspensions were centrifuged at 2,000 rpm for 5 min to settle the undissolved drug to the bottom of the microcentrifuge tube. The supernatants were then filtered through 0.8 μm syringe filters to obtain the saturated BIO solutions. A UV SpectraMax M2 spectrophotometer (Molecular Devices, Sunnyvale, Calif., USA) was used to measure BIO concentrations at 260 nm.
In Vitro Release of BIO from Hydrogel
The release rate of the physically entrapped BIO from PF127 hydrogels (20, 25, and 30% w/v), was studied by a membrane-less experiment, as reported previously[33-35]. Briefly, samples of 1 mL of polymer solutions containing 0.5 mg of BIO were transferred into screw cap tubes and incubated in a water bath at 37° C. until the gels were formed. After gelation, 2 mL of phosphate-buffered saline (PBS; pH 7.4) containing 0.5% Tween 80 pre-equilibrated at 37° C. were gently laid over the surface of the hydrogels and incubated in a water bath at 37° C. with continuous gentle shaking. To measure the release of BIO, release medium (2 mL) were taken at regular time intervals and replaced with an equal volume of pre-equilibrated fresh releasing buffer. The concentration of BIO was determined by measuring the absorbance at 260 nm using a Molecular Device's Spectramax M2 (Sunnyvale, Calif., USA). The release study was performed in triplicate.
The erosion time of PF127 hydrogel formulations (20, 25, and 30% w/v) was determined by performing the weight remaining (%) experiment, as reported by others[33-35]. Briefly, samples of 1 mL of polymer solutions were transferred into screw cap tubes and incubated in a water bath at 37° C. until the gels were formed. After gelation, the original weight of the hydrogel samples was measured as (W0). Subsequently, 2 mL of PBS (pH 7.4) pre-equilibrated at 37° C. were gently laid over the surface of the hydrogels and incubated in a water bath at 37° C. with continuous gentle shaking. The weight of remaining hydrogels (Wt) was measured at regular time intervals after completely blotting off the buffer. Erosion study was performed in triplicate. Weight remaining (%) was calculated as:
The impact of selected PF127 hydrogel formulation (25% w/v of mixed F127-PPi and F127, 50:50% w/w) and F127 hydrogel (25% w/v) (with or without BIO) on cell viability were assessed using CCK-8 assay. The BIO concentration in all BIO-containing formulations is 100 nM. Briefly, mouse preosteoblast MC3T3-L1 cell line was cultured in cell culture medium (alpha-MEM) with 10% (v/v) FBS and 1% (v/v) Penicillin/Streptomycin. The cells were incubated to 90% confluence under standard conditions at 37° C. in humidified atmosphere with 5% CO2. The hydrogels were extracted in alpha-MEM at 37° C. for 24 hr according to the ISO Standard 10993-12[34, 35]. The ratio between the surface area of the hydrogels and the volume of medium was 1.25 cm2/mL. Undiluted extracts were used for the assay. Cells were grown in 96 well plates (1×104 cells/well) and incubated for 24 hr at 37° C. The cells were then treated with either media only, PF127 extract, PF127-BIO extract, F127 extract, F127-BIO extract, or free BIO, and the plates were incubated at 37° C. for 24 and 48 hr. At each follow-up time point, CCK-8 reagent (10 μL) was added to each well and further incubated for 4 hr at 37° C. The absorbance was measured at 450 nm using a Molecular Device's Spectramax M2 microplate reader (Sunnyvale, Calif., USA).
Gelation temperature was determined by measuring the storage modulus (G′) and loss modulus (G″) of samples in the temperature sweep mode[36, 37]. Solutions with w/v concentrations ranging between 20 and 40% were prepared as described above. Each sample was uniformly loaded between the Peltier plate of the rheometer (TA Instruments AR1500ex) and a 60 mm-diameter, 1° cone geometry at 3° C. The linear viscoelastic region of each sample was pre-determined at 45° C. by using the oscillation amplitude function, and the following condition was chosen: strain of 0.1%, and angular frequency of 1 rad/s. Then, the G′ and G″ of each sample were measured for the temperature range from 3° C. to 45° C. by using the oscillation temperature sweep function of the rheometer (heating step: 1° C., soak time: 2 min for each temperature increase). The gelation temperature of each sample was determined as the temperature when G′ and G″ become equal.
The viscosity of gel phase was also investigated at constant temperature by flow sweep[30] (37° C., shear rate from 1 to 100 s−1) using the rheometer and a 25 mm-diameter parallel plate. Samples were dispensed on the Peltier plate of the rheometer, heated to 37° C. and maintained at 37° C. for 15 min to reach thermal stability before isothermally tested.
Ten-month-old female Sprague Dawley rats (retired breeders, Envigo) were acclimated for one week prior to experiment. The animals (n=48) were randomly assigned into the following groups (Table 2): healthy control, experimental periodontitis (EP) treated with saline, EP treated with 25% w/v of mixed F127-PPi and F127 hydrogel (50:50% w/w, containing 100 μM of BIO) (PF127-BIO), EP treated with 25% w/v of F127 hydrogel (containing 100 μM of BIO) (F127-BIO), EP treated with 25% w/v of PF127 hydrogel, and EP treated with free BIO (100 μM). Using silk ligatures, the experimental periodontitis was induced as described previously[32, 38]. Briefly, rats were first anesthetized in an isoflurane chamber with a 1% to 4% isoflurane in 100% O2. After taking the body weight, the rats were positioned with a nose cone supplied with 0.5% to 2% isoflurane and 100% O2 to maintain anesthesia during the entire procedure. To induce experimental periodontitis, a 4-0 silk ligature was gently tightened subgingivally around the maxillary 2nd molars (M2). Following ligature placement, different treatments (10 μL) were locally delivered between the maxillary 1st molar (M1) and 2nd molar (M2) once each week for 3 weeks. After one week, the ligatures were removed. All animals were euthanized at week 4. The entire palate including all three molars was dissected and fixed in 10% formalin prior to micro-CT and histological analyses. All animals-related experiments were approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Nebraska Medical Center (UNMC).
All palate samples (including all three molars) were evaluated for alveolar bone quality using a high-resolution X-ray microtomography system (Skyscan 1172, Bruker, Kontich, Belgium), references to previous studies[32, 38]. The X-ray source was set as follows: 70 kV and 141 μA, resolution 12.9 μm, exposure time 1880 ms, and aluminum filter 0.5 mm-thick. To generate 3D images, scanning raw data were reconstructed using NRecon software. Sagittal sections were generated using CT-Analyzer software. To evaluate bone erosion, the distance from cementoenamel junction (CEJ) to alveolar bone crest (ABC) was determined using Skyscan Data viewer software. A longer distance from CEJ to ABC suggests more bone loss. For the analysis of histomorphometric parameters, such as bone volume (BV) and trabecular thickness (Tb.Th), a polygonal region of interest (ROI) between M1 and M2 was identified. The ROI was determined from the distopalatal of M1 to the mesiopalatal of M2 (length), 130 slices below the CEJ of M1 and M2 (height), and from the palatal side to the buccal side of M1 and M2 (width).
As described previously[39], femurs of these tested rats were also collected and scanned to assess the potential systemic effect of BIO. The X-ray source was set as the follows: voltage was 70 kV, current was 141 μA, exposure time was 700 ms, resolution was 8.6 μm, and aluminum filter was 0.5 mm-thick. The 3-D imagine were generated using the Skyscan NRecon and Skyscan DataViewer software. For bone quality analysis, a consistent polygonal ROI of trabecular bone at the distal femur was selected and the ROI was determined from 20 slices to 100 slices proximal to the growth plate. The bone histomorphometric parameters, including mean bone volume (BV), bone volume/tissue volume (BV/TV), trabecular thickness (Tb.Th) and bone mineral density (BMD) were determined using CT-Analyzer software.
At the completion of the μ-CT scanning, palates were decalcified for two weeks using 14% EDTA solution. Following decalcification, tissues were embedded in paraffin to obtain 4 μm thick sagittal sections. The slides were hematoxylin and eosin (H&E) stained for microscopic observation. To probe the presence of inflammatory cells between M1 and M2 and osteoclasts in the alveolar crest, a pathologist (SML) blind to experimental group assignment, evaluated the slides semi-quantitatively using an Olympus BX53 microscope. A semi-quantitative scoring system[32, 40, 41] was used to evaluate inflammatory cells, where 0 is negative, 1 is less than 30% of the affected tissues, 2 is some inflammatory cells (30-60%), and 3 is many inflammatory cells (>60%). Similarly, osteoclasts on the alveolar crest were evaluated using a semi-quantitative scoring system[32, 42] where 0 is negative, 1 is a few osteoclasts lining less than 5% of alveolar bone surface, 2 is some osteoclasts (5-25%), and 3 is many osteoclasts (25-50%). Immunohistochemical (IHC) staining of β-catenin was performed using primary antibody (rabbit monoclonal anti-β-catenin antibody, Abcam, ab32572; 1:400 dilution). After deparaffinization and rehydration, sections were incubated in citrate buffer (pH=6.0, 0.1 M) for antigen retrieval, washed, and then incubated in hydrogen peroxide. Sections were then blocked and incubated with the primary antibody, followed by incubation with the secondary antibody. The antibody complexes were visualized using the DAB chromogen. Hematoxylin was used for counterstaining. The staining intensity was independently evaluated by a pathologist (SML) using a scale of from 0 to 3, where 0 is negative, 1 is weak staining, 2 is moderate staining, and 3 is strong staining[19, 43]. SML's scoring was calibrated by another examiner (YA) who evaluated a stack of slides and then compared with the SML's scores.
All the generated data were expressed as the mean±SD (standard deviation). Statistical analyses were carried out using Prism 8.0 software (GraphPad, San Diego, Calif.). The Analysis of Variance (ANOVA) was used to analyze continuous outcomes among more than three groups. Tukey's pairwise post-hoc testing was performed for multiple comparisons. β-value<0.05 was considered statistically significant.
The in vitro binding of the PF127 hydrogel (25% w/v) to HA was analyzed to predict their affinity to bone in vivo. As shown in
The solubility of BIO in PF127 and F127-containing solutions of different concentrations was analyzed and compared at 4° C. with solution pH=7. As shown in
In Vitro Release of BIO from PF127 Hydrogel
The releasing kinetics of BIO from PF127 hydrogels (20, 25, and 30% w/v) was studied at 37° C. As shown in
The PF127 hydrogels erosion behavior was characterized by measuring weight remaining (%) at regular incubation time intervals. The results correlate with the release study and shown to be a function of the concentration of hydrogel. As shown in
To assess the safety of PF127 hydrogel comparing to F127 which is known to be biocompatible, mouse osteoblast MC3T3-L1 cells were treated with PF127, PF127-BIO, F127 and F127-BIO culture media extracts, or free BIO (100 nM) for 24 hr and 48 hr, and cell viability was defined using the CCK-8 assay (
Gelation temperature (Tgel) was determined based on the temperature sweep measurements of storage and loss modulus, G′ and G″ (
Viscosity measurements were also performed on PF127 and F127 hydrogels with and without BIO at 37° C. to study the effect of the pyrophosphorolation and drug content on their viscous property (
As presented in
To study the impacts of different treatment on inflammatory cells, osteoclasts, and β-catenin, images of stained tissue sections (
In this example, simvastatin (SIM) was used as the therapeutic agent. The preparation of PF127 was described in Example 1.
Film hydration method: An excess amount of SIM was dissolved in methanol solution of PF127/F127. Methanol was evaporated to form a film and then on the following day hydration was done with iced water for 30 min to prevent formation of gel. Free drug was removed after centrifugation.
Solvent evaporation method: PF127/F127 and SIM were dissolved in acetone and then added dropwise to iced water with stirring. Acetone was evaporated overnight. Free drug was removed after centrifugation.
Direct dissolution method: Iced PF127/F127 solution was prepared first and an excess amount of SIM was added and mixed for 48 hr. Free drug was removed after centrifugation.
Results are shown in Table 4. Based upon this result direct dissolution method was used in the preparation of the SIM-loaded PF127/F127 hydrogel.
Phase transition of SIM-loaded PF127/F127 hydrogel is shown in
The experimental process is described in Example 1. The grouping and treatment are shown in Table 4.
As shown in
This application claims the priority to U.S. Provisional Application No. 62/835,542, filed on Apr. 18, 2019, and the disclosures of which are hereby incorporated by reference.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/CN2020/085549 | 4/20/2020 | WO | 00 |
| Number | Date | Country | |
|---|---|---|---|
| 62835542 | Apr 2019 | US |
